A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Summary

The overall objective of this Phase 1 study is to evaluate the safety, PK, and anti-tumor activity of 12 weeks of daily oral dosing with HP518 after selecting the RP2D of HP518 based on assessments of multiple dose escalation in patients with progressive mCRPC.

Timeline

Start

2021-12-14

Primary completion

2024-01-22

Completion

2024-01-22

Publications

• Azad AA, Gurney H, Underhill C, Horvath L, Voskoboynik M, Li X, King I, Shao L, Dai Y, Perabo F. Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity. Invest New Drugs. 2025 Apr;43(2):435-445. doi: 10.1007/s10637-025-01533-8. Epub 2025 Apr 28.

Drugs

Indications